↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Mobia Medical$MOBI · filed: 🫧 Edgar looked up MOBIA MEDICALCheck ▾Close ▴
What Mobia Medical filed
🫧 Edgar looked up MOBIA MEDICAL, INC. ($MOBI). Last filing: 10-Q, 2026-11-05. 5 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Mobia Medical’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
Mobia Medical set terms for a $150 million IPO this week, marking the first pure-play nerve stimulation device maker to price since Nevro Corp shed 56% from its 2021 peak. The Morrisville, North Carolina company holds investigational-stage technology for non-opioid pain management but carries no revenue, no FDA clearance, and no distribution agreements into a market where reimbursement codes determine viability.
The offering surfaces during a twelve-month window in which medtech IPO proceeds fell 41% year-over-year, per Renaissance Capital tracking through Q4 2024. Mobia's timing reflects either opportunistic venture exit mechanics or legitimate confidence in neuromodulation's secular tailwinds—the global spinal cord stimulation market runs at a 7.2% CAGR through 2030, driven by opioid-alternative mandates from Medicare Advantage plans. The company's lead device targets chronic back pain, a $635 billion annual U.S. cost burden, but clinical trial readouts remain six quarters out and commercialization likely extends into 2027.
The structural question for allocators: whether Mobia's technology differentiation justifies pre-revenue pricing in a category where Boston Scientific and Medtronic command 68% combined market share. Nevro's collapse—from a $4.8 billion peak valuation to $1.1 billion today—demonstrates how quickly reimbursement headwinds and sales execution misses compress multiples when clinical superiority fails to translate into durable margin expansion. Mobia's S-1 filing discloses $89 million in net losses since inception, with cash burn accelerating as it funds two pivotal trials. The IPO proceeds fund commercialization infrastructure and working capital, standard language that signals eighteen months of runway before either a follow-on raise or partnership necessity.
Family offices and strategic allocators should watch three catalysts with specific timing. First, Mobia's pivotal trial interim data releases in Q3 2025, which will either validate differentiated efficacy claims or expose the device as incrementally better at best. Second, CMS's proposed 2026 physician fee schedule drops in July 2025, and any neuromodulation reimbursement code adjustments will reprice the entire sector within trading days. Third, Boston Scientific's acquisition appetite—the company deployed $1.2 billion on tuck-in medtech deals in 2024—and whether Mobia's technology merits inbound interest before it faces commercialization risk.
The IPO prices into a market where medtech valuations compress 22% from 2021 peaks, but neuromodulation's non-opioid positioning holds optionality that pure orthopedic or cardiovascular plays lack. The risk is execution.
Branded by POPS4 · proof in 60 seconds
For the principal
Flag this for the healthcare allocation sleeve—pre-revenue medtech IPOs require secondary diligence on reimbursement pathway and trial design before considering any direct position.
For the operator
Track Nevro's next earnings call for reimbursement commentary—any CMS coding updates will reprice Mobia's valuation before the company ever generates revenue.
For the house
Named-account exclusion—pre-revenue neuromodulation carries binary trial risk and reimbursement dependency we avoid until FDA clearance and twelve-month commercial traction.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.